Chuan Shi1, Lan Kang1, Shuqiao Yao2, Yibin Ma1, Tao Li1, Ying Liang1, Zhang Cheng1, Yifeng Xu3, Jianguo Shi4, Xiufeng Xu5, Congpei Zhang6, Donald R Franklin7, Robert K Heaton7, Hua Jin8, Xin Yu9. 1. Peking University Sixth Hospital, Beijing, China; Peking University Institute of Mental Health, Beijing, China; NHC Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China; The National Clinical Research Center for Mental Health Disorders (Peking University Sixth Hospital), Beijing, China. 2. The Medical Psychological Research Center, Second Xiangya Hospital, Central South University, Changsha, Hunan, China. 3. Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 4. Xian Mental Health Center, New Qujiang District, Xian, Shanxi, China. 5. Department of Psychiatry, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. 6. The First Haerbin Psychiatric Hospital, Haerbin, Heilongjiang, China. 7. Department of Psychiatry, University of California at San Diego, San Diego, CA, USA. 8. Department of Psychiatry, University of California at San Diego, San Diego, CA, USA. Electronic address: hjin@ucsd.edu. 9. Peking University Sixth Hospital, Beijing, China; Peking University Institute of Mental Health, Beijing, China; NHC Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China; The National Clinical Research Center for Mental Health Disorders (Peking University Sixth Hospital), Beijing, China. Electronic address: yuxin@bjmu.edu.cn.
Abstract
BACKGROUND: The MATRICS consensus cognitive battery (MCCB) has been widely used to evaluate cognitive deficits in schizophrenia (SCZ), however, no study has formally examined the validity of the MCCB in Chinese SCZ. This study compared Chinese SCZ patients with healthy Chinese controls on the MCCB and some additional neurocognitive tests to determine if the Chinese MCCB is an optimal battery to assess the cognitive deficits in Chinese SCZ patients. METHOD: The study enrolled and examined 230 patients met DSM-IV criteria for SCZ and 656 healthy controls matched for gender, age and education. Besides the MCCB, we also included some additional neurocognitive tests that have been widely used in patients with schizophrenia. We selected MCCB and non-MCCB tests with large effect size, to assemble a new "optimal battery" and compared its performance with that of the standard MCCB. RESULTS: Comparing the putative "optimal" battery with the original MCCB, more patients with SCZ were identified as cognitively impaired according to the criteria of GDS ≥ 0.50 for the optimal battery (166 vs 135, or 72.2% vs 58.7%). The rate of cognitive impairment according to MCCB GDS in patients with SCZ who were currently working, ever worked and never worked are 45.5%, 61.6% and 70.8% (p = 0.051), whereas the optimal battery GDS showed 56.4%, 74.8%, 91.7% (p = 0.003), respectively. CONCLUSIONS: Our study needs validation with independent samples but suggests that the current "optimal" cognitive battery could be more sensitive than the widely used MCCB in detecting SCZ related cognitive impairment in China.
BACKGROUND: The MATRICS consensus cognitive battery (MCCB) has been widely used to evaluate cognitive deficits in schizophrenia (SCZ), however, no study has formally examined the validity of the MCCB in Chinese SCZ. This study compared Chinese SCZ patients with healthy Chinese controls on the MCCB and some additional neurocognitive tests to determine if the Chinese MCCB is an optimal battery to assess the cognitive deficits in Chinese SCZ patients. METHOD: The study enrolled and examined 230 patients met DSM-IV criteria for SCZ and 656 healthy controls matched for gender, age and education. Besides the MCCB, we also included some additional neurocognitive tests that have been widely used in patients with schizophrenia. We selected MCCB and non-MCCB tests with large effect size, to assemble a new "optimal battery" and compared its performance with that of the standard MCCB. RESULTS: Comparing the putative "optimal" battery with the original MCCB, more patients with SCZ were identified as cognitively impaired according to the criteria of GDS ≥ 0.50 for the optimal battery (166 vs 135, or 72.2% vs 58.7%). The rate of cognitive impairment according to MCCB GDS in patients with SCZ who were currently working, ever worked and never worked are 45.5%, 61.6% and 70.8% (p = 0.051), whereas the optimal battery GDS showed 56.4%, 74.8%, 91.7% (p = 0.003), respectively. CONCLUSIONS: Our study needs validation with independent samples but suggests that the current "optimal" cognitive battery could be more sensitive than the widely used MCCB in detecting SCZ related cognitive impairment in China.
Authors: Jason E Schillerstrom; Patricia Sawyer Baker; Richard M Allman; Bunja Rungruang; Edward Zamrini; Donald R Royall Journal: Neuroepidemiology Date: 2007-06-19 Impact factor: 3.282
Authors: Keith H Nuechterlein; Michael F Green; Robert S Kern; Lyle E Baade; Deanna M Barch; Jonathan D Cohen; Susan Essock; Wayne S Fenton; Frederick J Frese; James M Gold; Terry Goldberg; Robert K Heaton; Richard S E Keefe; Helena Kraemer; Raquelle Mesholam-Gately; Larry J Seidman; Ellen Stover; Daniel R Weinberger; Alexander S Young; Steven Zalcman; Stephen R Marder Journal: Am J Psychiatry Date: 2008-01-02 Impact factor: 18.112
Authors: Robert S Kern; James M Gold; Dwight Dickinson; Michael F Green; Keith H Nuechterlein; Lyle E Baade; Richard S E Keefe; Raquelle I Mesholam-Gately; Larry J Seidman; Cathy Lee; Catherine A Sugar; Stephen R Marder Journal: Schizophr Res Date: 2010-12-14 Impact factor: 4.939